April 24 (Reuters) - GSK plc:
* US FDA ACCEPTS NEW INDICATION FILING FOR JEMPERLI
* 23 AUGUST 2024 ASSIGNED AS PRESCRIPTION DRUG USER FEE ACT ACTION DATE FOR FDA DECISION Source text for Eikon: Further company coverage:
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
1,734 GBX | +0.29% | +4.87% | +19.54% |
10:43am | GSK : UBS remains its Buy rating | ZD |
May. 03 | GSK : DZ Bank remains Neutral | ZD |
April 24 (Reuters) - GSK plc:
* US FDA ACCEPTS NEW INDICATION FILING FOR JEMPERLI
* 23 AUGUST 2024 ASSIGNED AS PRESCRIPTION DRUG USER FEE ACT ACTION DATE FOR FDA DECISION Source text for Eikon: Further company coverage:
1st Jan change | Capi. | |
---|---|---|
+19.54% | 88.72B | |
+26.08% | 662B | |
+22.27% | 546B | |
-4.77% | 359B | |
+16.97% | 323B | |
+5.69% | 289B | |
+13.68% | 234B | |
+4.23% | 198B | |
-10.80% | 194B | |
+8.08% | 167B |